Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials

Documenti analoghi

• Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
  di: Hirotaka Watada, et al.
  Pubblicazione: (2024)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  di: Peter Rossing, et al.
  Pubblicazione: (2025)
• Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials
  di: Harpreet S. Bajaj, et al.
  Pubblicazione: (2024)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  di: Xichen Tong, et al.
  Pubblicazione: (2026)
• Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
  di: Ulrike Hövelmann, et al.
  Pubblicazione: (2024)